Orasure Technologies (OSUR) AI Stock Analysis

• Market Cap: $176.46M
• Dividend Yield: N/A
• Average Volume (3M): 715.36K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: -43.95%
• EPS Growth: -620.21%
• Country: US
• Employees: 501
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.19
• Shares Outstanding: 71,733,530
• 10 Day Avg. Volume: 558,035
• 30 Day Avg. Volume: 715,356
• PEG Ratio: 0.10
• Price to Book (P/B): 0.65
• Price to Sales (P/S): 1.45
• P/FCF Ratio: 11.40
• Enterprise Value/Market Cap: 0.18
• Enterprise Value/Revenue: 0.25
• Enterprise Value/Gross Profit: 0.62
• Enterprise Value/Ebitda: -0.61
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.86
• Revenue Forecast (FY): $117.18M

• Rating: 48 Neutral
• Price Target: $2.50 ▲(5.04% Upside)

Orasure Technologies' overall stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flow issues. While strategic initiatives and a strong balance sheet provide some optimism, the bearish technical indicators and poor valuation metrics weigh heavily on the score.

Positive Factors

Strategic Acquisitions

The acquisition of BioMedomics expands OraSure's diagnostic portfolio, leveraging existing sales channels and enhancing its market position in the diagnostics sector.

Strong Financial Position

A strong cash position and zero debt provide OraSure with financial flexibility to invest in growth opportunities and weather operational challenges.

Public Health Program Renewal

Renewal of the HIV self-test program ensures continued revenue and support for OraSure's public health initiatives, reinforcing its role in healthcare solutions.

Negative Factors

Revenue Decline in International Diagnostics

A significant decline in international diagnostics revenue due to slower orders and funding changes poses a challenge to OraSure's global market presence.

U.S. Diagnostics Revenue Decline

Declining U.S. diagnostics revenue, impacted by staffing and budget issues, may affect OraSure's domestic market performance and growth potential.

Continued Financial Losses

Ongoing financial losses highlight operational inefficiencies, which could hinder OraSure's ability to achieve profitability and sustain long-term growth.

Orasure Technologies Business Overview & Revenue Model

Company Description

OraSure Technologies, Inc. is a leader in the field of oral fluid diagnostics and medical devices, primarily focusing on the development and sale of products for the detection of infectious diseases and for drug testing. The company operates in two main sectors: the infectious disease testing market and the substance abuse testing market. Its core products include rapid diagnostic tests for HIV, HCV, and other infectious diseases, as well as oral fluid collection devices used for drug testing and other applications.

How the Company Makes Money

OraSure Technologies generates revenue primarily through the sale of its diagnostic products and testing services. Key revenue streams include sales from its OraQuick rapid HIV tests, which are used in various healthcare settings, and its testing solutions for hepatitis C. The company also earns revenue from its collection devices, which are utilized in drug testing programs. Significant partnerships with governmental health organizations, pharmaceutical companies, and healthcare providers enhance its market reach and drive sales. Additionally, OraSure's involvement in research and development grants and collaborations further contributes to its earnings, positioning it as a vital player in public health initiatives.

Orasure Technologies Financial Statement Overview

Summary

Orasure Technologies faces significant profitability and cash flow challenges, with negative margins and declining cash flow. The balance sheet remains a relative strength due to low leverage, but the company must address its operational inefficiencies to improve financial health.

Income Statement

Orasure Technologies has experienced a decline in profitability, with negative net profit and EBIT margins in the TTM period. Revenue growth is modest at 2.13% TTM, but historical revenue has been volatile. The company faces challenges in maintaining profitability, as evidenced by negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet shows a strong equity position with a low debt-to-equity ratio of 0.037 in the TTM period, indicating low leverage. However, the return on equity is negative, reflecting ongoing profitability challenges. The equity ratio remains stable, suggesting a solid capital structure.

Cash Flow

Cash flow metrics indicate significant challenges, with negative free cash flow growth and operating cash flow. The free cash flow to net income ratio is positive, suggesting some ability to convert earnings into cash, but overall cash flow performance is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	125.70M	185.83M	405.47M	387.48M	233.67M	171.72M
Gross Profit	50.80M	79.39M	179.42M	148.44M	117.60M	101.87M
EBITDA	-51.50M	-13.55M	64.35M	10.29M	846.00K	3.44M
Net Income	-60.24M	-19.50M	53.66M	-17.13M	-23.00M	-14.92M
Balance Sheet
Total Assets	423.10M	479.66M	482.85M	444.18M	460.99M	454.47M
Cash, Cash Equivalents and Short-Term Investments	216.48M	267.76M	290.41M	110.85M	153.04M	209.40M
Total Debt	13.46M	14.60M	13.50M	12.55M	12.27M	6.13M
Total Liabilities	61.12M	69.32M	52.17M	79.75M	80.46M	55.90M
Stockholders Equity	361.98M	410.34M	430.67M	364.43M	380.53M	398.57M
Cash Flow
Free Cash Flow	-43.65M	23.58M	131.28M	-111.11M	-83.50M	-23.12M
Operating Cash Flow	-39.92M	27.37M	141.58M	-47.20M	-35.38M	5.81M
Investing Cash Flow	-7.88M	-39.03M	66.15M	21.09M	-5.50M	-14.03M
Financing Cash Flow	-11.94M	-4.18M	-3.02M	-3.83M	-2.82M	92.48M

Orasure Technologies Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Neutral. The current price of 2.38 is above the 20-day moving average (MA) of 2.38, below the 50-day MA of 2.69, and below the 200-day MA of 2.99, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 48.16 is Neutral, neither overbought nor oversold. The STOCH value of 54.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OSUR.

Orasure Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	68 Neutral	$177.94M	34.90	9.95%	―	6.23%	283.88%
UTMD	63 Neutral	$177.87M	15.71	9.59%	2.19%	-12.35%	-17.20%
STXS	60 Neutral	$247.71M	―	-170.24%	―	19.61%	-3.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSUR	48 Neutral	$176.46M	―	-15.30%	―	-43.95%	-620.21%
SMTI	41 Neutral	$194.44M	―	-27.19%	―	30.55%	-340.19%

Orasure Technologies Corporate Events

OraSure Technologies Executives Adopt Stock Trading Plans

On December 1, 2025, OraSure Technologies announced that its President and CEO, Carrie Eglinton Manner, and CFO, Kenneth McGrath, adopted Rule 10b5-1 trading plans for purchasing the company’s common stock. These plans are part of the company’s ongoing share repurchase program and are structured to comply with the Securities Exchange Act of 1934 and the company’s Insider Trading Policy. The trading plans allow each executive to potentially purchase up to $165,000 of shares within six months after a specified commencement date, with trading beginning after a cooling-off period. This move is expected to align the interests of the executives with those of the shareholders, potentially impacting the company’s market perception and stakeholder confidence.

OraSure Technologies Reports Q3 2025 Financial Results

OraSure Technologies announced its financial results for the third quarter of 2025, reporting $27.1 million in revenue. Despite challenges related to funding uncertainties for public health programs, the company is optimistic about returning to growth in 2026 through product diversification and new product launches. The company is focusing on decentralizing diagnostics to make healthcare more accessible and personalized, with upcoming products like the Sherlock over-the-counter molecular self-test for Chlamydia and Gonorrhoeae and the Colli-Pee urine self-collection for sexually transmitted infections.

OraSure Technologies Announces Board Leadership Changes

On October 28, 2025, OraSure Technologies announced the resignation of Mara G. Aspinall from her position as director and chair of the Board, with no disputes cited as the cause. John P. Kenny, a current board member, has been appointed as the new chair. Additionally, Steven Boyd has been appointed as a Class II director, effective the same day, and will serve on the Audit Committee and the Nominating and Corporate Governance Committee. Boyd qualifies as an independent director and will receive an initial equity award valued at $100,000, which will vest in two years.